Nima Sharifi1, Elaine M Hurt, Suneetha B Thomas, William L Farrar. 1. Cancer Stem Cell Section, Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA. nima.sharifi@utsouthwestern.edu
Abstract
PURPOSE: Advanced prostate cancer is first treated with androgen deprivation therapy. However, tumors become resistant to and grow despite castrate levels of testosterone. Growth and proliferation of CRPC is mediated by gain-of-function changes in the AR and AR reactivation. Expression of manganese superoxide dismutase (SOD2), which regulates cellular ROS, is markedly down-regulated in CRPC when compared with hormone-responsive tumors. EXPERIMENTAL DESIGN: Here, we knocked down SOD2 expression in AR-expressing LNCaP prostate cancer cells and determined gene expression changes, transcription factor binding, and AR transcription activity in SOD2 knockdown cells. RESULTS: SOD2 knockdown results in an increase in ROS. Gene expression changes induced by SOD2 knockdown results in the up-regulation of genes that are also androgen responsive and 46% of genes up-regulated 2-fold by the androgen ligand R1881 are also up-regulated to the same extent with SOD2 knockdown. The induction of many of these genes with SOD2 knockdown, such as VEGFA and FKBP5, is reversible with the antioxidant N-acetylcysteine, suggesting that this mechanism is directly linked to ROS. Furthermore, an array for transcription factor DNA-binding activity shows that SOD2 knockdown induces DNA binding by several transcription factors, including AR. SOD2 knockdown-induced AR activation was confirmed by electrophoretic mobility shift assay and luciferase activity, and both were readily reversible with N-acetylcysteine. CONCLUSIONS: These findings show that down-regulation of SOD2 induces AR activity in a ROS-dependent manner, and suggest that there may be a role for antioxidant therapy in CRPC.
PURPOSE:Advanced prostate cancer is first treated with androgen deprivation therapy. However, tumors become resistant to and grow despite castrate levels of testosterone. Growth and proliferation of CRPC is mediated by gain-of-function changes in the AR and AR reactivation. Expression of manganese superoxide dismutase (SOD2), which regulates cellular ROS, is markedly down-regulated in CRPC when compared with hormone-responsive tumors. EXPERIMENTAL DESIGN: Here, we knocked down SOD2 expression in AR-expressing LNCaPprostate cancer cells and determined gene expression changes, transcription factor binding, and AR transcription activity in SOD2 knockdown cells. RESULTS:SOD2 knockdown results in an increase in ROS. Gene expression changes induced by SOD2 knockdown results in the up-regulation of genes that are also androgen responsive and 46% of genes up-regulated 2-fold by the androgen ligand R1881 are also up-regulated to the same extent with SOD2 knockdown. The induction of many of these genes with SOD2 knockdown, such as VEGFA and FKBP5, is reversible with the antioxidant N-acetylcysteine, suggesting that this mechanism is directly linked to ROS. Furthermore, an array for transcription factor DNA-binding activity shows that SOD2 knockdown induces DNA binding by several transcription factors, including AR. SOD2 knockdown-induced AR activation was confirmed by electrophoretic mobility shift assay and luciferase activity, and both were readily reversible with N-acetylcysteine. CONCLUSIONS: These findings show that down-regulation of SOD2 induces AR activity in a ROS-dependent manner, and suggest that there may be a role for antioxidant therapy in CRPC.
Authors: Bruno Perillo; Maria Neve Ombra; Alessandra Bertoni; Concetta Cuozzo; Silvana Sacchetti; Annarita Sasso; Lorenzo Chiariotti; Antonio Malorni; Ciro Abbondanza; Enrico V Avvedimento Journal: Science Date: 2008-01-11 Impact factor: 47.728
Authors: Samuel E DePrimo; Maximilian Diehn; Joel B Nelson; Robert E Reiter; John Matese; Mike Fero; Robert Tibshirani; Patrick O Brown; James D Brooks Journal: Genome Biol Date: 2002-06-14 Impact factor: 13.583
Authors: Farideh Mehraein-Ghomi; Hirak S Basu; Dawn R Church; F Michael Hoffmann; George Wilding Journal: Cancer Res Date: 2010-05-11 Impact factor: 12.701
Authors: Nima Sharifi; Jun Qi; Susan Bane; Shubhada Sharma; Rui Li; Robert Robey; William D Figg; William L Farrar; David G I Kingston Journal: Mol Pharm Date: 2010-10-07 Impact factor: 4.939
Authors: Joo Hyoung Lee; Minsung Kang; Hong Wang; Gurudatta Naik; James A Mobley; Guru Sonpavde; W Timothy Garvey; Victor M Darley-Usmar; Selvarangan Ponnazhagan Journal: FASEB J Date: 2017-01-09 Impact factor: 5.191
Authors: Elena V Fernandez; Kelie M Reece; Ariel M Ley; Sarah M Troutman; Tristan M Sissung; Douglas K Price; Cindy H Chau; William D Figg Journal: Mol Pharmacol Date: 2015-03-31 Impact factor: 4.436
Authors: Wanling Xie; Sarah Drouin; Mari Nakabayashi; Mark Pomerantz; Gwo-Shu Mary Lee; Philip W Kantoff; Nima Sharifi Journal: Prostate Date: 2016-06-21 Impact factor: 4.104
Authors: Kathleen C Light; Neeraj Agarwal; Eli Iacob; Andrea T White; Anita Y Kinney; Timothy A VanHaitsma; Hannah Aizad; Ronald W Hughen; Lucinda Bateman; Alan R Light Journal: Psychoneuroendocrinology Date: 2013-09-06 Impact factor: 4.905
Authors: Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair Journal: Antioxid Redox Signal Date: 2014-01-22 Impact factor: 8.401